Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 13/20 | 1.00 |
| ▸ | CLK1 | P49759 | 7/20 | 1.00 |
| ▸ | CLK2 | P49760 | 7/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 4/20 | 1.00 |
| ▸ | PRKCA | P17252 | 4/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CCND3 | P30281 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | CCND1 | P24385 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | CDK7 | P50613 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028175 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| SCHEMBL5839925 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| SCHEMBL29386738 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| SCHEMBL5839928 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| SCHEMBL5840189 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL30139897 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL2515988 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL2515986 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL30555179 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL2515982 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2020-12-15 | — | — | US | claimed |
| EP-3825692-B1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2024-09-04 | — | — | EP | disclosed |
| US-11337981-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3553186-B1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | INBIOMOTION SL (ES) | 2021-11-17 | — | — | EP | disclosed |
| EP-3825692-A1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | Fundació Institut de Recerca Biomèdica (IRB Barcelona) (ES) | 2021-05-26 | — | — | EP | disclosed |
| US-20200390772-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL | 2020-12-17 | — | — | US | disclosed |
| EP-3272880-B1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF METASTATIC CANCER | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2020-11-25 | — | — | EP | disclosed |
| EP-2971113-B1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2020-08-12 | — | — | EP | disclosed |
| US-10722515-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2020-07-28 | — | — | US | disclosed |
| EP-2836837-B1 | METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2020-04-22 | — | — | EP | disclosed |
| US-9925202-B2 | Treatment of lymphangioleiomyomatosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3272880-A2 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF METASTATIC CANCER | Fundació Institut de Recerca Biomèdica IRB (Barcelona) (ES) | 2018-01-24 | — | — | EP | disclosed |
| EP-3091085-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS | Institució Catalana de Recerca I Estudis Avançats (ES) | 2016-11-09 | — | — | EP | disclosed |
| US-20160022706-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022706-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2975138-A2 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | Fundació Institut de Recerca Biomèdica (IRB Barcelona) (ES) | 2016-01-20 | — | — | EP | disclosed |
| EP-2626431-B1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS | FUNDACIÓ INST DE RECERCA BIOMÈDICA IRB BARCELONA (ES) | 2015-09-16 | — | — | EP | disclosed |
| EP-2626431-A2 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS | Fundació Privada Institut de Recerca Biomèdica (ES) | 2013-08-14 | — | — | EP | disclosed |
| US-7091346-B1 | Purine derivatives and processes for their preparation | NOVARTIS AG (CH) | 2006-08-15 | — | — | US | disclosed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337981-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | CLK2, CLK1, CLK3 | CDK1 6/4885CLK1 2/4885CLK2 1/4885 |
| US-20200390772-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | CLK2, CLK1, CLK3 | CDK1 6/4885CLK1 2/4885CLK2 1/4885 |
| US-10722515-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | CLK2, CLK1, CLK3 | CDK1 6/4885CLK1 2/4885CLK2 1/4885 |
| US-20160022706-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | PTGER1, PTGS1, PTGES | CDK1 397/4885CLK1 879/4885CLK2 1201/4885 |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | CDK1 2928/4885CLK1 2678/4885CLK2 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.